Pieris Pharmaceuticals Valuation

Pieris Pharmaceuticals Investor Information

About 53.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.1. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pieris Pharmaceuticals recorded a loss per share of 12.11. The entity had not issued any dividends in recent years. The firm had 1:80 split on the 23rd of April 2024. Based on the key indicators related to Pieris Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Pieris Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.

Pieris Pharmaceuticals Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pieris Pharmaceuticals has an asset utilization ratio of 110.68 percent. This implies that the Company is making $1.11 for each dollar of assets. An increasing asset utilization means that Pieris Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Pieris Pharmaceuticals Ownership Allocation

The market capitalization of Pieris Pharmaceuticals is $21.14 Million. Over half of Pieris Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Pieris Pharmaceuticals Profitability Analysis

The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M).

Investing in growth stocks can be very risky. If the company such as Pieris Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

If you are still planning to invest in Pieris Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pieris Pharmaceuticals' history and understand the potential risks before investing.